REQUEST FOR APPLICATIONS:
NOVEL APPROACHES TO ADDRESS DISORDERED EATING AND EATING
DISORDERS IN TYPE 1 DIABETES

PURPOSE
JDRF is soliciting Letters of Intent (LOI’s) from single investigators or groups of investigators to (1) conduct behavioral interventions to treat or prevent eating disorders (ED) or disordered eating behaviors (DEB) in type 1 diabetes (T1D), or (2) perform non-interventional studies to develop knowledge and tools critical to prevention and care of DEB/ED in T1D.

BACKGROUND

People with T1D have a 2-3 fold higher risk of developing eating disorders than their peers without diabetes, and a significant number of people with T1D have disordered eating behaviors but do not meet full diagnostic criteria for ED. Over the past 30 years, psychological and behavioral science has steadily increased the evidence base of eating disorders and disordered eating behaviors in people with T1D, the associated risk factors, and the adverse outcomes such as increased rates of severe diabetes complications and high A1C, but much is still under-investigated.

Early detection and targeted prevention strategies could reduce the likelihood of development of a clinical ED. To develop effective approaches to prevention and early intervention models, increased knowledge of the etiology of DEB and ED is needed.

Importantly, there is also a need for successful diabetes specific DEB and ED treatment interventions that improve both psychological and glycemic outcomes. To date, there is a lack of effective clinical treatments specific to DEB or ED in T1D and the majority of intervention studies have been conducted in relatively small sample sizes. Larger clinical trials of diabetes specific, likely multidisciplinary, behavioral interventions are necessary to improve health care and outcomes. Additionally, there is a need to develop interventions with strong potential for uptake in diverse diabetes care settings and the need to examine preliminary implementation outcomes.

OBJECTIVE & SCOPE

The overall objective of this RFA is to advance new research across the disordered eating continuum in type 1 diabetes, to develop prevention strategies, develop effective interventions and to ultimately incorporate these new insights and interventions into clinical practice. LOIs should clearly define the population to be studied, including status of disorder (e.g. eating disorder/disordered eating/ at risk), age, etc.

Proposals should take an implementation focused approach to intervention development and testing, acknowledging that many people with T1D will receive care from providers unaffiliated with specialty diabetes or specialty psychological centers. The goal is to ensure that the resultant interventions are acceptable, feasible, scalable and implementable in clinical care.

Applications that include collaborative and multidisciplinary approaches are of particular interest. Applications should propose a plan for integrating their discoveries to improve health and health care
delivery. Applicants invited to full proposal may be asked to collaborate if the projects are complementary.

Examples of pertinent deliverables include, but are not limited to:

- Behavioral or multidisciplinary treatment interventions of DEB or ED that improve psychological measures and glycemic outcomes in adolescents and/or adults.
- Improved definitions and classifications of DEB or ED in people with type 1 diabetes
- Improvement of existing outcomes measures and instruments for detection and screening
- Early detection strategies and prevention strategies for DEB or ED
- Elucidating the associations and consequences of diabetes-related psychosocial factors such as diabetes distress, diabetes burnout, fear of hypoglycemia/hyperglycemia and others, on eating behavior
- Understanding resources needed in diabetes care settings to deliver prevention strategies or interventions

Applicants are encouraged to consult with JDRF Scientific Staff to discuss the alignment of their proposal to this RFA as they develop the project study concept.

FUNDING MECHANISM

In response to this announcement, LOI's can be submitted under the following mechanism:

Strategic Research Agreement (SRA)

For Strategic Research Agreements, proposed budgets for projects should not exceed $1,500,000 USD (including 10% indirect costs) total costs for up to four years. The level of funding will vary depending on the scope and overall objectives of the proposal. For more information on the Strategic Research Agreement (SRA) grant mechanism please refer to our website: https://grantcenter.jdrf.org/information-for-applicants/grant-mechanism-descriptions/strategic-research-agreements/

Under the terms of the grant award, written semi-annual reports will be required from the funded investigator as a basis for continued support. Investigators funded through this RFA will be required to participate in regular meetings with JDRF staff and share progress and data under confidentiality.

ELIGIBILITY

Applicants must hold an M.D., Ph.D., or equivalent academic degree and hold a faculty position or equivalent at a college, university, medical school, or comparable institution. Applications may be submitted by US or foreign non-profit organizations, public or private, such as colleges, universities, hospitals, laboratories, units of state or local governments, or eligible agencies of the federal government. For clinical studies, applicants must hold an appointment or joint appointment in a subspecialty of clinical medicine and conduct human clinical research.

Projects involving parties with complementary expertise are highly encouraged to submit to this RFA. This may include collaborations between research and clinical groups, research groups with expertise in Ecological Momentary Assessment, Patient Reported Outcomes development or educational expertise, expertise in implementation science, and expertise in public-private partnerships.
There are no citizenship requirements. To assure continued excellence and diversity among applicants and awardees, this RFA welcomes applications from all qualified individuals and encourages applications from persons with disabilities, women, and members of minority groups underrepresented in the sciences.

**LETTER OF INTENT**

Prospective applicants should submit a Letter of Intent, [2 pages maximum] online via RMS360 (http://jdrf.smartsimple.us) to be considered for a full proposal request. The LOI template provided on the RMS360 website must be used to complete the application.

**PROPOSAL**

An approved Letter of Intent is required prior to submission of a full proposal. Upon notification of a request for a full proposal, the application must be completed using the templates provided on the RMS360 (http://jdrf.smartsimple.us). Proposal section templates in MS Word, [10 pages maximum] should be type-written, single-spaced and in typeface no smaller than 10-point font and have no more than six vertical lines per vertical inch. Margins, in all directions, must be at least ½ inch. Complete information should be included to permit review of each application without reference to previous applications.

Note that all applications involving human subject research must include supplemental information to address subject safety, study design and investigational product information. More details can be found in the Human Subject Research Guidelines.

JDRF follows the U.S. National Institutes of Health (NIH) guidelines for studies including human subjects, including the common rule changes: https://nexus.od.nih.gov/all/2019/01/07/nih-implementation-of-the-final-rule-on-the-federal-policy-for-the-protection-of-human-subjects-common-rule/

**SCIENTIFIC REVIEW CRITERIA**

Applications will be subjected to confidential external scientific review and evaluated on the following:

- Significance
- Relevance
- Approach
- Innovation
- Investigator Experience
- Environment
- Resource sharing plan

**PROJECTED TIMELINE**

- RFA Release Date: .......................................................... September 27, 2021
- Letter of Intent Deadline....................................................October 27, 2021
- Notification of LOI Outcome.................................................November 3, 2021
- Full Proposal Deadline.....................................................December 6, 2021
- Earliest Response to Applicants.......................................... April, 2022
- Earliest Anticipated Start Date............................................ June, 2022
SUBMISSION INSTRUCTIONS
Applicants must register as an applicant and submit their application in response to this RFA using RMS360, JDRF’s grant management system (https://jdrf.smartsimple.us).

PROGRAM CONTACTS
Scientific Inquiries may be addressed to:
Jeannette Soderberg, Ph.D.
Director, European Research
JDRF International
jsoderberg@jdrf.org

Administrative Inquiries may be addressed to:
Tamara Croland, MPA
Associate Director, Program Administration
JDRF International
tcroland@jdrf.org

If you have any grant-specific questions as you work within RMS360, please contact the administrative contact listed above.

For any non-grant-specific inquiries or issues, please contact SmartSimple Support Services via email support@smartsimple.com or phone (866) 239 - 0991. Support hours are Monday through Friday between 5:00am and 9:00pm US Eastern Standard Time

ABOUT JDRF INTERNATIONAL:
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal. For more information, visit www.jdrf.org.